Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reiterated by Aegis in a research report issued to clients and investors on Thursday.

Other research analysts have also issued reports about the company. Jefferies Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Thursday, September 8th. Brean Capital reiterated a “buy” rating and set a $18.00 price objective on shares of Nektar Therapeutics in a research note on Friday, August 5th. Piper Jaffray Cos. set a $25.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Saturday, October 1st. Finally, Zacks Investment Research upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, September 29th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $20.50.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 0.31% during midday trading on Thursday, reaching $12.79. 464,242 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $13.72 and a 200-day moving average of $15.71. Nektar Therapeutics has a 1-year low of $10.52 and a 1-year high of $19.98. The company’s market capitalization is $1.95 billion.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The firm earned $36.30 million during the quarter, compared to analyst estimates of $32.42 million. During the same period in the prior year, the company posted ($0.06) earnings per share. The business’s revenue for the quarter was down 39.4% compared to the same quarter last year. Equities analysts expect that Nektar Therapeutics will post ($1.07) earnings per share for the current fiscal year.

WARNING: This news story was originally published by Financial Market News and is the propert of of Financial Market News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this news story can be accessed at http://www.financial-market-news.com/nektar-therapeutics-nktr-earns-buy-rating-from-aegis/1208558/.

In related news, CEO Howard W. Robin sold 93,458 shares of the firm’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $13.88, for a total value of $1,297,197.04. Following the transaction, the chief executive officer now owns 122,908 shares in the company, valued at $1,705,963.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Chess sold 12,000 shares of the firm’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $19.21, for a total value of $230,520.00. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of NKTR. UBS Asset Management Americas Inc. boosted its position in Nektar Therapeutics by 30.3% in the first quarter. UBS Asset Management Americas Inc. now owns 132,265 shares of the biopharmaceutical company’s stock valued at $1,819,000 after buying an additional 30,786 shares in the last quarter. Geode Capital Management LLC boosted its position in Nektar Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 979,790 shares of the biopharmaceutical company’s stock valued at $13,472,000 after buying an additional 72,107 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Nektar Therapeutics during the first quarter valued at about $834,000. BNP Paribas Arbitrage SA boosted its position in Nektar Therapeutics by 31.9% in the second quarter. BNP Paribas Arbitrage SA now owns 80,962 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 19,599 shares in the last quarter. Finally, Capstone Asset Management Co. boosted its position in Nektar Therapeutics by 9.5% in the second quarter. Capstone Asset Management Co. now owns 48,679 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 4,240 shares in the last quarter. Institutional investors and hedge funds own 85.87% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.